Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Monday, Benzinga reports.
Separately, Weiss Ratings raised shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 9th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Clene has an average rating of “Moderate Buy” and an average price target of $34.00.
Check Out Our Latest Stock Report on CLNN
Clene Stock Performance
CLNN traded up $0.21 during midday trading on Monday, reaching $3.31. 58,843 shares of the company were exchanged, compared to its average volume of 220,715. The company has a market cap of $43.00 million, a price-to-earnings ratio of -0.94 and a beta of 0.91. Clene has a one year low of $3.02 and a one year high of $13.50. The company’s fifty day moving average price is $4.04 and its 200 day moving average price is $5.33.
Clene (NASDAQ:CLNN – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.06 million. As a group, sell-side analysts anticipate that Clene will post -1.70 earnings per share for the current fiscal year.
About Clene
Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.
Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.
See Also
- Five stocks we like better than Clene
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
- Insider Buying Is Rising at These 3 Regional Banks, But the Details Matter
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
